Healthcare Industry News: Protalix BioTherapeutics
News Release - March 1, 2007
Orthodontix Announces Name Change to Protalix BioTherapeutics, Inc.CARMIEL, Israel, March 1 (HSMN NewsFeed) -- Orthodontix, Inc. (OTC Bulletin Board: PXBT; "Orthodontix") today announced that it has changed its name to Protalix BioTherapeutics, Inc. The trading symbol for the Company's common stock will change at the open of business on Thursday, March 1, 2007, to PXBT.
Protalix's proprietary technology is based on its plant cell culture and bioreactor system which provides an effective and scaleable cell system for industrial production of recombinant biopharmaceuticals. Protalix has recently announced that it has completed Phase I clinical studies for its enzyme therapy for Gaucher Disease, under an FDA Investigational New Drug study. Pending FDA approval, Protalix intends to pursue advanced clinical studies for its enzyme therapy for Gaucher Disease and to advance additional recombinant biopharmaceutical drug development programs.
Source: Protalix BioTherapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.